Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance
The failure of complete remissions to reliably translate into cures in acute myeloid leukemia (AML) can be explained by the leukemia stem cell (LSC) paradigm, which hypothesizes that rare leukemia cells with stem cell features, including self-renewal capa
- PDF / 383,228 Bytes
- 17 Pages / 439.37 x 666.142 pts Page_size
- 46 Downloads / 229 Views
Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance Theodoros Karantanos and Richard J. Jones
Abstract The failure of complete remissions to reliably translate into cures in acute myeloid leukemia (AML) can be explained by the leukemia stem cell (LSC) paradigm, which hypothesizes that rare leukemia cells with stem cell features, including self-renewal capacity and drug resistance, are primarily responsible for both disease maintenance and relapses. Traditionally, the ability to generate AML in immunocompromised mice were how these so-called LSCs were identified. Only those rare AML cells characterized by a hematopoietic stem cell (HSC) CD34+CD38− phenotype were believed capable of generating leukemia in immunocompromised mice, but more recently, significant heterogeneity in the phenotypes of engrafting AML cells has been demonstrated. Moreover, AML cells that engraft immunocompromised mice do not necessarily represent either the founder clone or those cells responsible for relapse. A recent study found that the most immature phenotype present in an AML was heterogeneous, but correlated with genetically defined risk groups and outcomes. Patients with AML cells expressing a primitive HSC phenotype (CD34+CD38− with high aldehyde dehydrogenase activity) manifested significantly lower complete remission rates, as well as poorer event-free and overall survivals. AMLs in which the most primitive cells displayed more mature phenotypes were associated with better outcomes. The strong clinical correlations suggest that the most immature phenotype detectable within a patient’s AML might serve as a biomarker for “clinically relevant” LSCs. The minimal residual disease state during first remission may be the optimal setting to study novel LSC-targeted therapies, since they may have limited activity against the bulk leukemia and will be utilized at lowest tumor burden as well as least tumor heterogeneity. Keywords Acute myeloid leukemia · Leukemia stem cells · Heterogeneity · CD34 · CD38 · Aldehyde dehydrogenase · CD33 · CD123 · CLL-1
T. Karantanos · R. J. Jones (*) The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA e-mail: [email protected] © Springer Nature Switzerland AG 2019 A. Birbrair (ed.), Stem Cells Heterogeneity in Cancer, Advances in Experimental Medicine and Biology 1139, https://doi.org/10.1007/978-3-030-14366-4_9
153
154
T. Karantanos and R. J. Jones
9.1 Introduction Acute myeloid leukemia (AML), the most common acute leukemia in adults (Jemal et al. 2010), is a clonal disorder defined by the accumulation of abnormally differentiated myeloid cells in the bone marrow. Despite the introduction of novel therapeutic approaches and significant improvements in the long-term outcomes of patients over the past two decades, AML remains a disease with an overall poor prognosis (Dohner et al. 2015; Maynadie et al. 2013); this includes high recurrence rates even in patients who achieve complete remission (CR) after induction chemotherapy (Dohner et al. 2015; Mayna
Data Loading...
